**8. Conclusion**

Significant advancements in pathogenic knowledge helped to improve the management and the prognosis of patients suffering from AAV. This group of rare systemic vasculitis has now earlier remissions and lower relapse rates but needs urgent and aggressive treatment based on corticosteroids and immunosuppressant agents most of the time. Nowadays, rituximab has gained popularity because of his efficiency and less toxic properties. It is now preferred in severe cases of GPA and MPA. It was even more potent than cyclophosphamide in relapsing forms of the diseases. Our understanding of the pathogenesis continues to expand, and targeting specific pathogenic pathways is needed to improve the outcome.
